Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G. · 2019

Read Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. by Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6562565.txt.

Description

Vigano and co-authors review adenosine, a metabolic brake on anti-tumor immunity, writing in Frontiers in Immunology. Stressed, oxygen-starved tumors leak ATP, and enzymes named CD39 and CD73 convert it stepwise into adenosine. In healthy tissue adenosine briefly calms inflammation after injury. In tumors it lingers, and the calm becomes a shield.

Adenosine dulls T cells, natural killer cells and dendritic cells while strengthening regulatory and suppressor cells. The review maps how levels are controlled, how its receptors signal, and what it does to each cell type around a tumor. It closes with the counterattack: drugs blocking CD39, CD73 or adenosine receptors, which in early studies restore T-cell attack, especially alongside checkpoint blockade or cell therapy.

Catalog record

CREATORVigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE156 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6562565

Browse the full library · About the Tower of Babel